Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Interstitial Cystitis Treatment Pipeline Review H2 2016

Monday, October 17, 2016 2:36
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2016’, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685892-interstitial-cystitis-painful-bladder-syndrome-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)
- The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects
- The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Complete report details @ https://www.wiseguyreports.com/reports/685892-interstitial-cystitis-painful-bladder-syndrome-pipeline-review-h2-2016

 

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Interstitial Cystitis (Painful Bladder Syndrome) Overview 8
Therapeutics Development 9
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) – Overview 9
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) – Comparative Analysis 10
Interstitial Cystitis (Painful Bladder Syndrome) – Therapeutics under Development by Companies 11
Interstitial Cystitis (Painful Bladder Syndrome) – Therapeutics under Investigation by Universities/Institutes 12
Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Interstitial Cystitis (Painful Bladder Syndrome) – Products under Development by Companies 16
Interstitial Cystitis (Painful Bladder Syndrome) – Products under Investigation by Universities/Institutes 17
Interstitial Cystitis (Painful Bladder Syndrome) – Companies Involved in Therapeutics Development 18
Allergan Plc 19
Aquinox Pharmaceuticals Inc. 20
Astellas Pharma Inc. 21
Kytogenics Pharmaceuticals, Inc. 22
Lipella Pharmaceuticals, Inc. 23
MediPost Co., Ltd. 24
UCB S.A. 25
Urigen Pharmaceuticals, Inc. 26
UroGen Pharmaceuticals, Ltd. 27
Interstitial Cystitis (Painful Bladder Syndrome) – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(heparin + lidocaine) – Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
AQX-1125 – Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ASP-6294 – Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Cartistem – Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
certolizumab pegol – Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
GM-0111 – Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
lidocaine hydrochloride – Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
LP-08 – Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
mesalamine – Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
MK-7264 – Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
NEO-5937 – Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
onabotulinumtoxinA – Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
onabotulinumtoxinA SR – Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
pentosan polysulfate sodium – Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
URG-801 – Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Interstitial Cystitis (Painful Bladder Syndrome) – Dormant Projects 77
Interstitial Cystitis (Painful Bladder Syndrome) – Discontinued Products 78
Interstitial Cystitis (Painful Bladder Syndrome) – Product Development Milestones 79
Featured News & Press Releases 79
May 25, 2016: Aquinox Announces Executive Appointments 79
May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results 79
May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego 81
Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA 81
Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration 82
Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference 82
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis 83
Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS 84
Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 84
Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 84
Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis 85
May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms 85
Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 86
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 87
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685892

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)          

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.